- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04141618
The Role of NLRP Gene Family (NLRP1~14) in Recurrent Miscarriage and Infertility
October 3, 2022 updated by: National Cheng-Kung University Hospital
Dr. Pao-Lin Kuo (Department of Obstetrics and Gynecology)
Development of mole was not associated with segregation of mutated NLRP7 allele in the haploid oocyte.
We hypothesize NLRP7 is a maternal factor involved in regulating early embryo development or embryo-uterine interaction.
In the proposed study, we seek to identify novel genetic variants and mutations of NLRP7 in women who experienced RM/HM.
Genetic association study and haplotype analysis are performed to test assocation between NLRP7 gene and female reproductive performance.
Immunohistochemical staining, RT-PCR, and Western blot analysis are used to investigate expression pattern of NLRP7 in endometrium and placenta.
Two approaches are used to characterize functional significance of genetic variants/mutations.
The first approach will be based on mutagenesis and the second approach will be based on induced pluripotent stem cells (iPSCs).
Results obtained from the proposed study will provide novel insight into mechanism of embryo development and implantation.
Study Overview
Status
Completed
Conditions
Detailed Description
Recurrent miscarriage (RM), defined as at least two consecutive fetal death or spontaneous abortions before the 20th week gestational age, occurred in about 1% to 5% couples.
The causes of RM include uterine factors, endocrine factors, thromobophilic factors, immunologic factors and genetic factors.
The hydatidiform mole (HM) can be divided into two separate syndromes: complete mole (CHM) and partial mole (PHM).
In the West, CHMs occur in approximately 1 in every 1500 pregnancies.
The incidence is higher in Latin America, Southeast Asia and the Middle East.
The cause of RM and HM are not known for the vast majority of cases.
The NLRP (Nucleotide-binding oligomerization domain, Leucine rich Repeat and Pyrin domain containing) family, also referred to as NALP family, is well known for its roles in apoptosis and inflammation.
Expression studies showed that twelve of the fourteen members of NLRP family express differentially in human oocytes and preimplantation embryonic cells, especially NLRP7, indicating important role of NLRP family in female reproduction.
Since 2006, mutations of NLRP7 have been found in women with repeated occurrence of molar pregnancy, repeated stillbirth or early spontaneous abortion.
In women who experienced RM/HM, we also found some novel mutations/genetic variants of NLRP7.
Taken together, these finding suggest RM and HM may share the same genetic etiology in some cases.
In addition, NLRP7 is a strong candidate gene for RM/HM.
A recent report showed chaotic cleavage abnormalities of embryos in patients with NLRP7 variants.
Study Type
Observational
Enrollment (Actual)
143
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tainan, Taiwan, 70428
- National Cheng-Kung University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Assuming that there are 300 cases and 300 controls enrolled, the underlying disease model is recessive, the disease prevalence is approximately 3% and the disease allele frequency is about 5%, this study has more than 80% power for detecting the SNP with an allele frequency greater than 10% and an allelic odds ratio greater than 1.4.
We assumed that the SNP is either the causal gene or in LD with the causal allele and power was calculated without multiple testing corrections.
Description
Inclusion Criteria:
Recurrent abortions and infertility treatments but combined with repetitive (more than two consecutive) implantation failure couples, rather than general infertility couples.
Exclusion Criteria:
Women who do not have recurrent miscarriage and infertility problems.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pregnancy outcome
Time Frame: 1 month at the end of pregnancy
|
Pregnancy and delivery of a normal baby is defined as normal outcome
|
1 month at the end of pregnancy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
spontaneous abortion
Time Frame: abortion before 12 weeks of gestation
|
fail to maintain pregnancy beyond 12 weeks
|
abortion before 12 weeks of gestation
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intrauterine fetal death
Time Frame: fetal death after 12 weeks of gestation
|
pregnancy beyond 12 weeks followed by death of the fetus
|
fetal death after 12 weeks of gestation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2011
Primary Completion (ACTUAL)
July 1, 2015
Study Completion (ACTUAL)
July 31, 2015
Study Registration Dates
First Submitted
April 7, 2014
First Submitted That Met QC Criteria
October 24, 2019
First Posted (ACTUAL)
October 28, 2019
Study Record Updates
Last Update Posted (ACTUAL)
October 4, 2022
Last Update Submitted That Met QC Criteria
October 3, 2022
Last Verified
October 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BR-100-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Esraa Gamal AhmedAin Shams Maternity HospitalUnknownUnexplained Female Infertility
-
King's College LondonNot yet recruitingInfertility | Infertility, Female | Infertility Unexplained | Infertility of Tubal Origin
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Wake Forest University Health SciencesWithdrawnUterine Diseases | Endometriosis | Infertility Unexplained | Endometrial Diseases | Infertility; Female, NonimplantationUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Pacific Fertility CenterTerminatedPrimary Female Infertility | Secondary Female Infertility
-
Istanbul University - Cerrahpasa (IUC)RecruitingInfertility | Sexual Dysfunction | Infertility, Male | Nurse's Role | Sexuality | Infertility; FemaleTurkey